Cargando…

Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*

OBJECTIVES: The long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) has recently been approved as a once-daily treatment for COPD. The objectives of this study were to determine the dose delivery characteristics of glycopyrronium and compare them with those of the LAMA tiotropium, both...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colthorpe, Paul, Voshaar, Thomas, Kieckbusch, Thomas, Cuoghi, Erika, Jauernig, Juergen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Maney Publishing 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937662/ https://www.ncbi.nlm.nih.gov/pubmed/27536432 http://dx.doi.org/10.3109/21556660.2013.766197

Ejemplares similares

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
por: Leaker, Brian R., et al.
Publicado: (2019)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
por: Crater, Glenn D., et al.
Publicado: (2022)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
por: Singer, David, et al.
Publicado: (2020)

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
por: Ferguson, Gary T., et al.
Publicado: (2020)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
por: Beeh, Kai M, et al.
Publicado: (2018)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
por: Salvi, Sundeep, et al.
Publicado: (2022)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
por: Mohan, V., et al.
Publicado: (2021)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023)

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD
por: Chapman, Kenneth R, et al.
Publicado: (2011)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
por: Katsumata, Mineo, et al.
Publicado: (2022)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery
por: Hassanpour Aghdam, Mehdi, et al.
Publicado: (2016)

Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
por: Rashid, Md Abdur, et al.
Publicado: (2019)

Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018)

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
por: Phillips, Jonathan E., et al.
Publicado: (2017)

Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler
por: Dolovich, Myrna B., et al.
Publicado: (2019)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study
por: Watz, Henrik, et al.
Publicado: (2021)

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler
por: Allan, Richard, et al.
Publicado: (2021)

Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations
por: Miyamoto, Kahori, et al.
Publicado: (2022)

Feedback systems in multi-dose dry powder inhalers
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gi2qeg1a39r3l2k63cla1g3tn4